ClinicalTrials.gg
RecruitingNCT06013592LEAP2-mealUpdated Jun 26, 2024

Gut Hormone LEAP2 in Metabolism and Eating Behaviour: Fixed Meal Testing

An interventional study of 0 kcal liquid meal and 600 kcal liquid meal in Eating Behavior, Obesity and Appetitive Behavior, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Imperial College London · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies in Feeding Behavior with a site in United Kingdom — 6 open to participants now, 7 under way, none of them phase 3. Feeding Behavior · United Kingdom.

Planned enrollment
33rd of 39
30 · median 100
Started
2023
with 5 others
No phase
39 of 52
3 open now
Registered
44th of 52
by date

Among the 52 studies in Feeding Behavior with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2023, is one of 39 with no phase, and was the 44th registered.

Feeding Behavior

988 studies on the registry are indexed under Feeding Behavior; 177 are open to participants now.

Browse Feeding Behavior studies →

Open to participants now

6 of the 52 studies in Feeding Behavior with a site in United Kingdom are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 112 Feeding Behavior studies recruiting now, 35 (31%) set no upper age limit and 71 (63%) stop at 75 or younger; 41 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Feeding Behavior with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this interventional study is to measure the blood levels of the gut hormones LEAP2 and acyl ghrelin (AG), appetite and food intake after consuming liquid meals of different caloric sizes, in healthy adults with and without obesity.

AG is a stomach-derived homone that increases appetite, and LEAP2 a liver-gut derived hormone that decreases appetite, which interferes the action of AG ant its receptor in the brain called the growth hormone secretagogue receptor (GHSR). Blood levels of AG and LEAP2 change in opposite directions after food intake (AG decreasing, LEAP2 increasing). AG is formed from an inactive version of hormone called desacyl ghrelin (DAG). Previous studies have shown that greater food intake leads to a greater decrease in blood levels of total ghrelin (AG + DAG), but this has not been studied for changes in blood AG or LEAP2 after eating. Blood levels of AG and total ghrelin when fasted and after food intake are lower, while blood levels of LEAP2 are higher, in adults with than those without obesity.

The main study questions are:

  1. Are there greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG after consuming larger meals (by amount of calories they contain)?
  2. Are greater decreases in appetite after connsuming larger meals related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG?
  3. Are greater decreases in food intake at a buffet lunch after consuming larger meals eaten a few hours previously related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG?
  4. Do the above findings differ between adults without obesity and with obesity?

At each of 4 study days, healthy adults (without and with obesity) will consume one size of a single liquid meal containing different amounts of calories (0, 600, 900 (group without obesity only), 1200, 1800 (group with obesity only) kilocalories, of identical total volume) after an overnight fast and have measurements of blood LEAP2 and AG and appetite ratings from 0 to 180 min, and have food intake at an ad libitum lunch measured at 180 mins. Food will be weighed and converted into kilocalories.

All participants will attend for all 4 study visits in a randomised order to receive one of the meal sizes at each visit, so that all 4 meal zizes are consumed over all 4 study visits: 0, 600, 900 (group without obesity), 1200, 1800 (group with obesity) kcal.

03

Conditions studied

  • Eating Behavior
  • Obesity
  • Appetitive Behavior

Keywords

  • LEAP2
  • ghrelin
  • appetite
  • food intake
  • eating behaviour
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 18 and 60 years;
  • Without obesity with (BMI) 18.0-29.9 kg/m2 or with obesity with BMI 30.0-50.0 kg/m2;
  • Healthy as determined by medical history and vital signs;
  • Capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form;
  • Participant is able to read, comprehend and record information written in English.

Exclusion criteria

Exclusion Criteria:

  • History of, or current abuse or dependence on alcohol or drugs;
  • Current smoker or less than 2 years since quitting (cigarette, cigars, e-cigarettes) or use of nicotine replacement therapy;
  • Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation;
  • History of type 1 or type 2 diabetes mellitus;
  • History of ischaemic heart disease, heart failure, cardiac arrhythmia, peripheral vascular, cerebrovascular disease or uncontrolled hypertension;
  • Current diagnosis of anaemia or iron deficiency;
  • Body weight instability (change in body weight of more than 5% over the preceding 3 months);
  • Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures;
  • abnormalities in screening blood tests abnormalities which in the opinion of the study physician, is clinically significant e.g. diabetes mellitus, hypothyroidism, renal impairment, abnormal liver function tests [, (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)] >3x , other than due to fatty liver disease; Current pregnancy or breast-feeding in female volunteers (the Investigators will recommend using for the duration of the visits to avoid participant drop-out);
  • Pulse rate \<40 or >100 beats per minute OR systolic blood pressure >160 and \<100 OR diastolic blood pressure >95 and \<50 in the semi-supine position;
  • Volunteer has participated in a clinical trial and has received an product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer);
  • Exposure to more than 3 new investigational medicinal products within 12 months prior to the scan;
  • Vegan, gluten or lactose-intolerant (as test meals in the paradigms may include animal products, dairy and wheat products);
  • Volunteers who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion;
  • Known history of SARS-CoV-2 infection (Covid-19) in the last 4 weeks;
  • Ongoing symptoms suggestive of complications from previous SARS-CoV-2 infection ('long Covid-19') such as loss or change in sense of smell or taste, shortness of breath, palpitations, lethargy;
  • SCOFF questionnaire score >1/5 indicating eating disorders (Luck et al. 2002);
  • criteria for alcohol use disorder (AUD) >2/11 indicating mild AUD (American-Psychiatric-Association 2013);
  • Participants who have had previous obesity surgery or are on medications for obesity;
  • Dutch Eating Behaviour Questionnaire (DEBQ) restraint score >3/5 indicating highly restrained eating behaviour.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Healthy adults without obesity

    Liquid meals with different caloric sizes (0, 600, 900, 1200 kcal) in within-participant cross-over design

    Dietary Supplement: 0 kcal liquid meal · Dietary Supplement: 600 kcal liquid meal · Dietary Supplement: 900 kcal liquid meal (only for group without obesity) · Dietary Supplement: 1200 kcal liquid meal

  • Experimental
    Healthy adults with obesity

    Liquid meals with different caloric sizes (0, 600, 1200, 1800 kcal) in within-participant cross-over design

    Dietary Supplement: 0 kcal liquid meal · Dietary Supplement: 600 kcal liquid meal · Dietary Supplement: 1200 kcal liquid meal · Dietary Supplement: 1800 kcal liquid meal (only for group with obesity)

Interventions

  • Dietary supplement0 kcal liquid meal

    Flavoured water, given as one meal at one study visit only

  • Dietary supplement600 kcal liquid meal

    Fortisip Compact Vanilla, given as one meal at one study visit only

  • Dietary supplement900 kcal liquid meal (only for group without obesity)

    Fortisip Compact Vanilla, given as one meal at one study visit only

  • Dietary supplement1200 kcal liquid meal

    Fortisip Compact Vanilla, given as one meal at one study visit only

  • Dietary supplement1800 kcal liquid meal (only for group with obesity)

    Fortisip Compact Vanilla, given as one meal at one study visit only

06

What researchers measure

Primary outcomes

  1. Post-prandial plasma concentration acyl ghrelin

    Incremental area under curve (iAUC) 0-180 minutes, units: pg/mL.hr

    Time frame: 0, 30, 60, 120, 180 minutes

  2. Post-prandial plasma concentration LEAP2

    Incremental area under curve (iAUC) 0-180 minutes, units: ng/mL.hr

    Time frame: 0, 30, 60, 120, 180 minutes

Secondary outcomes

  1. Visual analogue scale ratings of appetite

    Incremental area under curve (iAUC) 0-180 minutes - units: mm.hr

    Time frame: 0, 30, 60, 120, 180 minutes

  2. Ad libitum food intake

    Total kilocalories eaten as % estimated resting energy expenditure (calculated from bio-impedance analysis determined fat free mass using Cunningham equation equating with lean body mass)

    Time frame: at 180 minutes

07

Study locations

1 of 1 sites recruiting
  • PsychoNeuroEndocrinology Research Group, Division of Psychiatry, Dept. of Brain Sciences, Imperial College London
    London, W12 0NN, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2025, 24 months after the start.

Of 503 non-industry interventional studies with no phase under Feeding Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 24 months is above that.

Counting every sponsor, half of 515 studies reached it within 14 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Aug 28, 2023
StartActual
Aug 29, 2023
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06013592
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Aug 29, 2023
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Jun 26, 2024

Study contacts

Tony Goldstone, MRCP PhD
Contact
tony.goldstone@imperial.ac.uk
+44 20 7594 5989
Tony Goldstone, MRCP PhD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion